Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X:
“LBA78: Anbenitamab + chemo vs. placebo + chemo after trastuzumab-containing treatment for GC/GEJC (KC-WISE)
- Anbenitamab: bispecific antibody binding distinct HER2 domains
- PFS: 7.2 vs. 2.7 mo, HR 0.25, p<0.0001
- OS: 19.6 vs. 11.5 mo, HR 0.29, p<0.00001″
More posts featuring ESMO25.